Literature DB >> 21656910

A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer.

Elizabeth R Remily-Wood1, Richard Z Liu, Yun Xiang, Yi Chen, C Eric Thomas, Neal Rajyaguru, Laura M Kaufman, Joana E Ochoa, Lori Hazlehurst, Javier Pinilla-Ibarz, Jeffrey Lancet, Guolin Zhang, Eric Haura, David Shibata, Timothy Yeatman, Keiran S M Smalley, William S Dalton, Emina Huang, Ed Scott, Gregory C Bloom, Steven A Eschrich, John M Koomen.   

Abstract

PURPOSE: The Quantitative Assay Database (QuAD), http://proteome.moffitt.org/QUAD/, facilitates widespread implementation of quantitative mass spectrometry in cancer biology and clinical research through sharing of methods and reagents for monitoring protein expression and modification. EXPERIMENTAL
DESIGN: Liquid chromatography coupled to multiple reaction monitoring (LC-MRM) mass spectrometry assays are developed using SDS-PAGE fractionated lysates from cancer cell lines. Pathway maps created using GeneGO Metacore provide the biological relationships between proteins and illustrate concepts for multiplexed analysis; each protein can be selected to examine assay development at the protein and peptide levels.
RESULTS: The coupling of SDS-PAGE and multiple reaction monitoring mass spectrometry screening has been used to detect 876 peptides from 218 cancer-related proteins in model systems including colon, lung, melanoma, leukemias, and myeloma, which has led to the development of 95 quantitative assays including stable-isotope-labeled peptide standards. Methods are published online and peptide standards are made available to the research community. Protein expression measurements for heat shock proteins, including a comparison with ELISA and monitoring response to the HSP90 inhibitor, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), are used to illustrate the components of the QuAD and its potential utility. CONCLUSIONS AND CLINICAL RELEVANCE: This resource enables quantitative assessment of protein components of signaling pathways and biological processes and holds promise for systematic investigation of treatment responses in cancer.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21656910      PMCID: PMC3530891          DOI: 10.1002/prca.201000115

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  51 in total

Review 1.  Proteomic contributions to personalized cancer care.

Authors:  John M Koomen; Eric B Haura; Gerold Bepler; Rebecca Sutphen; Elizabeth R Remily-Wood; Kaaron Benson; Mohamad Hussein; Lori A Hazlehurst; Timothy J Yeatman; Lynne T Hildreth; Thomas A Sellers; Paul B Jacobsen; David A Fenstermacher; William S Dalton
Journal:  Mol Cell Proteomics       Date:  2008-07-29       Impact factor: 5.911

2.  Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells.

Authors:  Pascale Flandrin; Denis Guyotat; Amélie Duval; Jérôme Cornillon; Emmanuelle Tavernier; Nathalie Nadal; Lydia Campos
Journal:  Cell Stress Chaperones       Date:  2008-04-03       Impact factor: 3.667

3.  Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin d.

Authors:  Fabiola Cervantes-Gomez; Ramadevi Nimmanapalli; Varsha Gandhi
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

4.  Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.

Authors:  Dongweon Song; Raghothama Chaerkady; Aik Choon Tan; Elena García-García; Anuradha Nalli; Ana Suárez-Gauthier; Fernando López-Ríos; Xian Feng Zhang; Anna Solomon; Jeffrey Tong; Margaret Read; Christian Fritz; Antonio Jimeno; Akhilesh Pandey; Manuel Hidalgo
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

Review 5.  Untangling the unfolded protein response.

Authors:  Emma L Davenport; Gareth J Morgan; Faith E Davies
Journal:  Cell Cycle       Date:  2008-01-09       Impact factor: 4.534

6.  HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma.

Authors:  Ramadevi Nimmanapalli; Elvira Gerbino; William S Dalton; Varsha Gandhi; Melissa Alsina
Journal:  Br J Haematol       Date:  2008-05-22       Impact factor: 6.998

7.  SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.

Authors:  Yutaka Okawa; Teru Hideshima; Paul Steed; Sonia Vallet; Steven Hall; Ken Huang; John Rice; Amy Barabasz; Brianna Foley; Hiroshi Ikeda; Noopur Raje; Tanyel Kiziltepe; Hiroshi Yasui; Sotaro Enatsu; Kenneth C Anderson
Journal:  Blood       Date:  2008-10-23       Impact factor: 22.113

8.  A database of mass spectrometric assays for the yeast proteome.

Authors:  Paola Picotti; Henry Lam; David Campbell; Eric W Deutsch; Hamid Mirzaei; Jeff Ranish; Bruno Domon; Ruedi Aebersold
Journal:  Nat Methods       Date:  2008-11       Impact factor: 28.547

Review 9.  Heat shock protein 90 as a drug target: some like it hot.

Authors:  Udai Banerji
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

10.  Serial dilution curve: a new method for analysis of reverse phase protein array data.

Authors:  Li Zhang; Qingyi Wei; Li Mao; Wenbin Liu; Gordon B Mills; Kevin Coombes
Journal:  Bioinformatics       Date:  2009-01-28       Impact factor: 6.937

View more
  33 in total

Review 1.  Integration of proteomics into systems biology of cancer.

Authors:  S Hanash; M Schliekelman; Q Zhang; A Taguchi
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2012-03-08

2.  Evaluating melanoma drug response and therapeutic escape with quantitative proteomics.

Authors:  Vito W Rebecca; Elizabeth Wood; Inna V Fedorenko; Kim H T Paraiso; H Eirik Haarberg; Yi Chen; Yun Xiang; Amod Sarnaik; Geoffrey T Gibney; Vernon K Sondak; John M Koomen; Keiran S M Smalley
Journal:  Mol Cell Proteomics       Date:  2014-04-23       Impact factor: 5.911

3.  Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.

Authors:  Yun Xiang; Elizabeth R Remily-Wood; Vasco Oliveira; Danielle Yarde; Lili He; Jin Q Cheng; Linda Mathews; Kelly Boucher; Christopher Cubitt; Lia Perez; Ted J Gauthier; Steven A Eschrich; Kenneth H Shain; William S Dalton; Lori Hazlehurst; John M Koomen
Journal:  Mol Cell Proteomics       Date:  2011-08-16       Impact factor: 5.911

4.  Multiplexed Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry Quantification of Cancer Signaling Proteins.

Authors:  Yi Chen; Kate J Fisher; Mark Lloyd; Elizabeth R Wood; Domenico Coppola; Erin Siegel; David Shibata; Yian A Chen; John M Koomen
Journal:  Methods Mol Biol       Date:  2017

5.  Body fluid identification by mass spectrometry.

Authors:  Heyi Yang; Bo Zhou; Haiteng Deng; Mechthild Prinz; Donald Siegel
Journal:  Int J Legal Med       Date:  2013-03-24       Impact factor: 2.686

6.  CPTAC Assay Portal: a repository of targeted proteomic assays.

Authors:  Jeffrey R Whiteaker; Goran N Halusa; Andrew N Hoofnagle; Vagisha Sharma; Brendan MacLean; Ping Yan; John A Wrobel; Jacob Kennedy; D R Mani; Lisa J Zimmerman; Matthew R Meyer; Mehdi Mesri; Henry Rodriguez; Amanda G Paulovich
Journal:  Nat Methods       Date:  2014-07       Impact factor: 28.547

Review 7.  Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays.

Authors:  Carol E Parker; Christoph H Borchers
Journal:  Mol Oncol       Date:  2014-03-20       Impact factor: 6.603

8.  Oxidized lipids block antigen cross-presentation by dendritic cells in cancer.

Authors:  Rupal Ramakrishnan; Vladimir A Tyurin; Vladimir A Tuyrin; Filippo Veglia; Thomas Condamine; Andrew Amoscato; Dariush Mohammadyani; Joseph J Johnson; Lan Min Zhang; Judith Klein-Seetharaman; Esteban Celis; Valerian E Kagan; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2014-02-19       Impact factor: 5.422

Review 9.  Clinical potential of mass spectrometry-based proteogenomics.

Authors:  Bing Zhang; Jeffrey R Whiteaker; Andrew N Hoofnagle; Geoffrey S Baird; Karin D Rodland; Amanda G Paulovich
Journal:  Nat Rev Clin Oncol       Date:  2019-04       Impact factor: 66.675

10.  Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.

Authors:  H Eirik Haarberg; Kim H T Paraiso; Elizabeth Wood; Vito W Rebecca; Vernon K Sondak; John M Koomen; Keiran S M Smalley
Journal:  Mol Cancer Ther       Date:  2013-03-28       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.